MEDVi Swaps PT-141 for Apomorphine in 2026 QUAD Formula
The company confirmed an ingredient change to its four-in-one combination product for the coming year.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 16 20:19 ETSource: The Manila Times
The wire
- 01MEDVi confirmed apomorphine replaces PT-141 in its 2026 QUAD four-in-one combination.
- 02Formulation changes in combination products affect prescribers and compounding supply chains.
- 03Reasons for the substitution and regulatory status were not stated.
From the source
Read at news.google.comMEDVi QUAD Formula Update Confirmed for 2026: Apomorphine Replaces PT-141 in Current 4-in-1 Combination